RedHill Biopharma Ltd. (NASDAQ: RDHL) announced it has acquired exclusive commercialization rights to two FDA-approved gastrointestinal drugs, Rebyota and Clenpiq ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE